Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Non-cash Items (2016 - 2019)

Historic Non-cash Items for Usana Health Sciences (USNA) over the last 9 years, with Q4 2019 value amounting to $821000.0.

  • Usana Health Sciences' Non-cash Items fell 9872.43% to $821000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $821000.0, marking a year-over-year decrease of 9872.43%. This contributed to the annual value of $821000.0 for FY2019, which is 9872.43% down from last year.
  • Per Usana Health Sciences' latest filing, its Non-cash Items stood at $821000.0 for Q4 2019, which was down 9872.43% from $64.4 million recorded in Q4 2018.
  • Usana Health Sciences' Non-cash Items' 5-year high stood at $83.5 million during Q1 2016, with a 5-year trough of $58000.0 in Q3 2015.
  • For the 5-year period, Usana Health Sciences' Non-cash Items averaged around $32.7 million, with its median value being $26.7 million (2017).
  • Examining YoY changes over the last 5 years, Usana Health Sciences' Non-cash Items showed a top increase of 1546603.77% in 2015 and a maximum decrease of 9976.35% in 2015.
  • Over the past 5 years, Usana Health Sciences' Non-cash Items (Quarter) stood at $130000.0 in 2015, then surged by 27722.31% to $36.2 million in 2016, then fell by 26.17% to $26.7 million in 2017, then soared by 141.02% to $64.4 million in 2018, then crashed by 98.72% to $821000.0 in 2019.
  • Its Non-cash Items was $821000.0 in Q4 2019, compared to $64.4 million in Q4 2018 and $26.7 million in Q4 2017.